Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis
Résumé
Purpose
Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.
Patients and method
We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.
Results
Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.
Conclusion
Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.
Domaines
Sciences du Vivant [q-bio]Origine | Fichiers produits par l'(les) auteur(s) |
---|